Fig. 2

SIRT7 enhances prostate cancer cell growth in vitro. a Protein level of SIRT7 in shNC and shSIRT7 groups of LNCap and 22Rv1 cell lines. b and c CCK8 assay of LNCap (b) and 22Rv1 (c) from control and SIRT7 knockdown group. d Presentative EdU immunofluorescent staining of LNCap and 22Rv1 from control and SIRT7 knockdown group. e Percentages of EdU-positive cells of the indicated groups. f and g Colony formation assay of shNC and shSIRT7 groups in LNCap and 22Rv1 cell lines. Each assay was performed in triplicate and the data are shown as the means ± SD. P-values were calculated by t-test (*P < 0.05; **P < 0.01; ***P < 0.001)